Clinical Pharmacology and Drug Toxicity Practice Questions

Q: A patient presented to the emergency department with an overdose of a drug, exhibiting increased salivation and increased bronchial secretions. On examination, the blood pressure was 88/60 mmHg, and the RBC cholinesterase level was reduced to 50% of normal. What should be the treatment for this individual?

Atropine. ***Atropine*** - The patient exhibits symptoms of **cholinergic crisis** (increased salivation, bronchial secretions, hypotension) and reduced RBC esterase, strongly indicative of **organophosphate poisoning**. - **Atropine** is the primary antidote, as it competitively blocks muscarinic acetylcholine receptors, reversing the parasympathetic effects. *Neostigmine* - **Neostigmine** is an **acetylcholinesterase inhibitor**, meaning it would worsen the cholinergic crisis by increasing acetylcholine levels further. - It is used in conditions like **myasthenia gravis** to improve muscle strength, not in organophosphate poisoning. *Flumazenil* - **Flumazenil** is an **antagonist of benzodiazepine receptors** and is used to reverse benzodiazepine overdose. - It has no role in treating organophosphate poisoning or cholinergic symptoms. *Physostigmine* - **Physostigmine** is also an **acetylcholinesterase inhibitor** that can cross the blood-brain barrier. - While it has some ophthalmic uses, it would exacerbate the cholinergic symptoms of organophosphate poisoning due to increased acetylcholine.

Q: A 23-year-old female underwent kidney transplantation and developed acute humoral rejection after 8 days, which was successfully managed with tacrolimus and another drug that suppresses both B and T lymphocytes. What is the drug that targets both B and T lymphocytes by inhibiting de novo synthesis of purines?

Mycophenolate mofetil. ***Mycophenolate mofetil*** - This drug inhibits **inosine monophosphate dehydrogenase**, an enzyme crucial for the **de novo synthesis of guanine nucleotides** in lymphocytes. - This selective inhibition effectively suppresses the proliferation and function of both **B and T lymphocytes**, making it a cornerstone in preventing transplant rejection. *Methotrexate* - **Methotrexate** is an **antimetabolite** that primarily inhibits **dihydrofolate reductase**, interfering with DNA synthesis and cell proliferation. - While it has immunosuppressive effects, its primary mechanism in inhibiting purine synthesis is not de novo synthesis in the same manner as mycophenolate mofetil. *Prednisone* - **Prednisone** is a **corticosteroid** that exerts its immunosuppressive effects through broad anti-inflammatory actions, genomic and non-genomic effects, affecting the function of various immune cells. - It does not specifically target **de novo purine synthesis** as its primary mechanism of immunosuppression. *Cyclophosphamide* - **Cyclophosphamide** is an **alkylating agent** that cross-links DNA strands, leading to cell cycle arrest and apoptosis, particularly in rapidly dividing cells like lymphocytes. - While it is a potent immunosuppressant affecting both B and T cells, its mechanism does not involve the inhibition of **de novo purine synthesis**.

Q: All of the following drugs cause hirsutism except:

Heparin. ***Heparin*** - Heparin is an **anticoagulant** medication used to prevent blood clots. - Its primary side effects include **bleeding**, **thrombocytopenia**, and **osteoporosis** with long-term use, but not hirsutism. *Phenytoin* - **Phenytoin** is an anticonvulsant commonly associated with **hirsutism** as a side effect. - It can cause excessive hair growth on the face, trunk, and extremities due to its effects on **hair follicles**. *Minoxidil* - **Minoxidil** is a vasodilator primarily used to treat **androgenetic alopecia** (hair loss), but it can cause **hirsutism** as a side effect, especially when used systemically. - When applied topically for hair regrowth, it can still lead to unwanted hair growth in other areas. *Corticosteroids* - Long-term or high-dose use of **corticosteroids** (e.g., prednisone) can cause a range of side effects, including **hirsutism**. - This is often part of a broader spectrum of **Cushingoid features**, such as moon facies and central obesity.

Q: In a post-renal transplant patient already on triple therapy with Cyclosporine, Azathioprine, and Prednisolone, which of the following drugs would NOT be added to this regimen?

FK 506. ***FK 506 (Tacrolimus)***- **FK 506** is tacrolimus, which is a calcineurin inhibitor like cyclosporine and should **NOT be added** to a regimen already containing cyclosporine due to overlapping mechanisms of action and increased toxicity risk [2].- Both tacrolimus and cyclosporine inhibit calcineurin, preventing T-cell activation. Using both simultaneously would provide no additional benefit but significantly increase nephrotoxicity and neurotoxicity [2, 3].- In clinical practice, tacrolimus may **replace** cyclosporine in triple therapy but is never used **concurrently** with it [2].*Cyclosporine*- **Cyclosporine** is already part of the described triple therapy regimen as the calcineurin inhibitor component.- It inhibits calcineurin phosphatase activity, preventing NF-AT dephosphorylation and subsequent IL-2 gene transcription, thereby suppressing T-cell activation [1].*Azathioprine*- **Azathioprine** is already part of the described triple therapy regimen as the antimetabolite component.- It is converted to 6-mercaptopurine, which inhibits purine synthesis and suppresses lymphocyte proliferation.*Prednisolone*- **Prednisolone** is already part of the described triple therapy regimen as the corticosteroid component.- It provides broad immunosuppression through anti-inflammatory effects and lymphocyte apoptosis.

Q: An 8-year-old child is brought to the emergency department after accidentally swallowing multiple tablets of a drug. The child developed severe diarrhea, polyuria, sweating, and respiratory difficulty. On examination, the pupil was constricted, and crepitations were heard on lung auscultation in the lower lobes of both lungs. There were no vascular or CNS effects. Which drug can cause these types of effects?

Neostigmine. ***Neostigmine***- **Neostigmine** is an **acetylcholinesterase inhibitor** that increases acetylcholine levels, leading to widespread **cholinergic effects** as observed (diarrhea, polyuria, sweating, constricted pupils, respiratory difficulty, and crepitations) [2].- **Key distinguishing feature:** Neostigmine is a **quaternary ammonium compound** that **does not cross the blood-brain barrier** [1], explaining the **absence of CNS effects** despite severe peripheral cholinergic toxicity.- This matches the clinical presentation perfectly: severe peripheral cholinergic symptoms without CNS involvement.*Physostigmine*- **Physostigmine** is a **tertiary amine** acetylcholinesterase inhibitor that **readily crosses the blood-brain barrier**, causing significant **CNS effects** (seizures, confusion, coma) [1].- The **absence of CNS symptoms** in this case definitively rules out physostigmine poisoning.- While it causes similar peripheral cholinergic effects, the lack of neurological symptoms is the critical differentiator.*Acetylcholine*- **Acetylcholine** itself is rapidly metabolized by acetylcholinesterase and cholinesterase enzymes, so it would not produce such **prolonged and severe effects** even if ingested.- Has **poor oral bioavailability** and would be broken down quickly in the GI tract.- As a direct agonist, any effects would be transient due to rapid **enzymatic breakdown**.*Bethanechol*- **Bethanechol** is a **direct muscarinic agonist** (quaternary ammonium) primarily used to stimulate bladder and bowel function [1].- While it can cause some peripheral cholinergic effects, it would not typically produce the **severe respiratory distress with crepitations** seen here.- The severity and widespread nature of symptoms are more characteristic of **acetylcholinesterase inhibitor toxicity** rather than direct muscarinic agonism [2].

Q: Drug-induced myopathy can be caused by all of the following except:

ciprofloxacin. ***Ciprofloxacin*** - **Ciprofloxacin**, a fluoroquinolone antibiotic, is primarily associated with **tendonitis and tendon rupture**, particularly the Achilles tendon. - While it can cause some musculoskeletal pain, it is **not a common cause of myopathy** or muscle damage with elevated muscle enzymes. *Atorvastatin* - **Statins** like atorvastatin are well-known causes of **drug-induced myopathy**, ranging from myalgia to severe rhabdomyolysis. - This effect is due to inhibition of **HMG-CoA reductase**, which can disrupt muscle cell membrane integrity. *D-penicillamine* - **D-penicillamine** can induce a variety of autoimmune phenomena, including muscle disorders resembling **myasthenia gravis** or **polymyositis**. - Its mechanism involves interfering with **collagen and elastin cross-linking**, and potentially promoting autoimmune responses against muscle components. *Chloroquine* - **Chloroquine** (and hydroxychloroquine) can cause a dose-dependent myopathy, characterized by **proximal muscle weakness** and elevated creatine kinase. - The medication accumulates in lysosomes, leading to **lysosomal vacuolar myopathy** and muscle fiber degeneration.

Q: Which of the following is not used in the treatment of organophosphorus poisoning?

Naltrexone. ***Naltrexone*** - **Naltrexone** is an **opioid receptor antagonist** primarily used in the management of **alcohol and opioid dependence**; it has no role in treating organophosphorus poisoning. - Its mechanism of action involves blocking opioid receptors, which is unrelated to the cholinergic crisis seen in organophosphorus toxicity. *Pralidoxime* - **Pralidoxime** is a **cholinesterase reactivator** that works by removing organophosphate molecules from acetylcholinesterase, thereby regenerating the enzyme and reversing nicotinic effects. - It is particularly effective if administered early in the course of poisoning, before **"aging"** of the enzyme occurs. *Atropine* - **Atropine** is a **muscarinic acetylcholine receptor antagonist** used to block the muscarinic effects of organophosphorus poisoning, such as **bronchospasm**, **bradycardia**, and **secretions**. - It does not reactivate cholinesterase or reverse nicotinic effects (e.g., muscle weakness), but it is crucial for managing life-threatening muscarinic symptoms. *Activated charcoal* - **Activated charcoal** is used for **gastrointestinal decontamination** in cases of oral organophosphorus ingestion. - It works by **adsorbing** the poison in the gastrointestinal tract, preventing its absorption into the systemic circulation.

Q: What is the primary metabolite of methanol that contributes to its toxicity and potential visual disturbances?

Formic acid. ***Formic acid*** - Methanol is metabolized by **alcohol dehydrogenase** to formaldehyde, which is then rapidly converted to **formic acid** by aldehyde dehydrogenase. - Formic acid is directly responsible for the **metabolic acidosis** and specific toxicity, including **retinal damage** leading to visual disturbances and blindness. *Uric acid* - **Uric acid** is a waste product of purine metabolism and is associated with gout, not methanol poisoning. - Its accumulation in the body is not due to methanol metabolism. *Lactic acid* - **Lactic acid** accumulates during anaerobic metabolism or in conditions like shock or severe hypoxia. - While methanol poisoning can cause **lactic acidosis**, lactic acid is not a primary metabolite of methanol itself. *Pyruvic acid* - **Pyruvic acid** is an intermediate in glycolysis and gluconeogenesis, and its metabolism is usually affected by various metabolic derangements. - It is not a direct metabolite of methanol responsible for its specific toxicity.

Q: Digoxin toxicity is increased by all except:

Hyperkalemia. ***Hyperkalemia*** - **Hyperkalemia** actually *reduces* the binding of digoxin to the Na+/K+ ATPase, thereby **decreasing** its pharmacological effect and the risk of toxicity. - While it can cause cardiac arrhythmias on its own, it does not increase the specific risk of digoxin toxicity. *Renal impairment* - **Digoxin** is primarily excreted by the **kidneys**, so **renal impairment** leads to reduced clearance and accumulation of the drug. - This increased drug concentration in the body significantly raises the risk of **digoxin toxicity**. *Hypercalcemia* - **Hypercalcemia** potentiates the effects of digoxin by increasing the intracellular calcium concentration, which can lead to enhanced contractility and increased risk of **arrhythmias**. - High calcium levels can exacerbate the cardiac side effects of digoxin toxicity, such as **AV blocks** and **ventricular arrhythmias**. *Hypomagnesemia* - **Hypomagnesemia** increases the binding of digoxin to the Na+/K+ ATPase, making the heart more sensitive to digoxin's effects. - Along with **hypokalemia**, **hypomagnesemia** is a common electrolyte imbalance that can precipitate or worsen digoxin toxicity, promoting **arrhythmias**.

Q: Which of these drugs can be given safely to a patient with renal disease?

Morphine. ***Morphine*** - Morphine is primarily metabolized in the **liver** and excreted as glucuronide conjugates, making it generally safer in patients with **renal impairment**. - While careful dosing and monitoring are still needed, its elimination is less dependent on **kidney function** compared to other drugs listed. *Phenacetin* - Phenacetin is an **NSAID** that is known to cause **analgesic nephropathy**, leading to chronic interstitial nephritis and papillary necrosis. - Its use is contraindicated in patients with existing **renal disease** due to the high risk of further kidney damage. *Tetracycline* - Tetracyclines can accumulate in patients with **renal impairment**, leading to increased side effects such as **nephrotoxicity** and increased **blood urea nitrogen (BUN)**. - Specifically, some tetracyclines (e.g., outdated tetracycline) can cause a **Fanconi-like syndrome** in susceptible individuals. *Aminoglycoside* - Aminoglycosides are extensively excreted by the kidneys and are highly **nephrotoxic**, causing acute tubular necrosis. - Their use in **renal disease** requires significant dose adjustments and careful monitoring of plasma levels to prevent further kidney damage and ototoxicity.

Question 1

A patient presented to the emergency department with an overdose of a drug, exhibiting increased salivation and increased bronchial secretions. On examination, the blood pressure was 88/60 mmHg, and the RBC cholinesterase level was reduced to 50% of normal. What should be the treatment for this individual?

Accepted Answer

Atropine

Answer

Physostigmine

Answer

Flumazenil

Answer

Neostigmine

Question 2

A 23-year-old female underwent kidney transplantation and developed acute humoral rejection after 8 days, which was successfully managed with tacrolimus and another drug that suppresses both B and T lymphocytes. What is the drug that targets both B and T lymphocytes by inhibiting de novo synthesis of purines?

Accepted Answer

Mycophenolate mofetil

Answer

Prednisone

Answer

Methotrexate

Answer

Cyclophosphamide

Question 3

All of the following drugs cause hirsutism except:

Accepted Answer

Heparin

Answer

Phenytoin

Answer

Minoxidil

Answer

Corticosteroids

Question 4

In a post-renal transplant patient already on triple therapy with Cyclosporine, Azathioprine, and Prednisolone, which of the following drugs would NOT be added to this regimen?

Accepted Answer

FK 506

Answer

Cyclosporine

Answer

Prednisolone

Answer

Azathioprine

Question 5

An 8-year-old child is brought to the emergency department after accidentally swallowing multiple tablets of a drug. The child developed severe diarrhea, polyuria, sweating, and respiratory difficulty. On examination, the pupil was constricted, and crepitations were heard on lung auscultation in the lower lobes of both lungs. There were no vascular or CNS effects. Which drug can cause these types of effects?

Accepted Answer

Neostigmine

Answer

Physostigmine

Answer

Acetylcholine

Answer

Bethanechol

Question 6

Drug-induced myopathy can be caused by all of the following except:

Accepted Answer

ciprofloxacin

Answer

d-penicillamine

Answer

chloroquine

Answer

atorvastatin

Question 7

Which of the following is not used in the treatment of organophosphorus poisoning?

Accepted Answer

Naltrexone

Answer

Pralidoxime

Answer

Atropine

Answer

Activated charcoal

Question 8

What is the primary metabolite of methanol that contributes to its toxicity and potential visual disturbances?

Accepted Answer

Formic acid

Answer

Uric acid

Answer

Lactic acid

Answer

Pyruvic acid

Question 9

Digoxin toxicity is increased by all except:

Accepted Answer

Hyperkalemia

Answer

Hypercalcemia

Answer

Hypomagnesemia

Answer

Renal impairment

Question 10

Which of these drugs can be given safely to a patient with renal disease?

Accepted Answer

Morphine

Answer

Aminoglycoside

Answer

Phenacetin

Answer

Tetracycline

Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity — MCQs

On this page

Practice by Chapter

Want unlimited practice?